Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer

PURPOSE: Clinical trials investigating therapies for metastatic breast cancer (mBC) generally use progression-free survival (PFS) as primary endpoint, which is not accepted as patient-relevant outcome within the German benefit assessment. Hence a validation of PFS as surrogate endpoint for overall s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lux, Michael Patrick, Böhme, Sarah, Hücherig, Stephanie, Jeratsch, Ulli, Kürschner, Niclas, Lüftner, Diana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586722/
https://www.ncbi.nlm.nih.gov/pubmed/31065873
http://dx.doi.org/10.1007/s10549-019-05262-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586722/
https://www.ncbi.nlm.nih.gov/pubmed/31065873
http://dx.doi.org/10.1007/s10549-019-05262-4

Ejemplares similares